
FDA approved Novartis’ secukinumab (Cosentyx) 150 mg for adults with polymyalgia rheumatica who respond inadequately to corticosteroids or cannot tolerate a taper. In the Phase 3 REPLENISH trial, secukinumab doubled sustained remission rates.
Vaccine conference, manufacturing shortages
over 24 years ago
Analytical Advances: Strategies in Clarifying Mammalian Culturesover 24 years ago
Analytical Advances: Using Image Informatics - Focusing Proteomicsover 24 years ago
The Not-So-Sure Thingover 24 years ago
Washington Report: Vaccine Shortages put Spotlight on Productionover 24 years ago
Guest Editorial: Validation Bingoover 24 years ago
Travel Notes: Yes, Virginia, There is Biotech in the Commonwealth





